A RARE TUMOR

Prog Urol. 2010 Jul;20(7):538-41. Epub 2010 Jan 6.
[Renal medullary carcinoma: remission with gemcitabine-cisplatin and review of therapeutic perspectives]

[Article in French]
Diao B, Paule B, Esquivel S, Abbou CC, Salomon L, De La Taille A.

Service d'urologie de l'hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Tassigny, 94010 Créteil, France. babacardiao104uro@yahoo.fr
Abstract

We report a case of renal medullary carcinoma concerning a 38-year-old woman. Heterozygote sickle cell trait was noticed in her past medical history. The physical examination was unremarkable. The CT-scan revealed a left renal mass of 48 mm x 20 mm, hypovascularised, located in the lower pole of the kidney with extension into the sinus. There were also enlarged lymph nodes laterally to aortic artery and between the aorta and the vena cava. A left radical nephrectomy with lymphadenectomy was performed. The histological examination with immuno-histo-chemical analysis revealed a renal medullary carcinoma T1N2R0 (TNM 2002). An adjuvant chemotherapy consisting of gemcitabine-cisplatin was administered. A regression of the residual lymph nodes was noticed after the six cycles of chemotherapy and the PET-Scan was negative. The patient underwent a second operation and the residual mass was excised. No tumor cell was found at the histological examination of the residual nodes. The patient had no clinical or radiological symptoms of progression eight months after the radical nephrectomy. We discuss the diagnostic criteria and analyse the therapeutic perspectives. Copyright 2009 Elsevier Masson SAS. All rights reserved.